AIM ImmunoTech Inc (AIM)
0.43
0.00 (0.00%)
USD |
NYAM |
Apr 24, 16:00
0.428
0.00 (0.00%)
After-Hours: 20:00
AIM ImmunoTech Cash from Financing (TTM): 0.485M for Dec. 31, 2023
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
Date | Value |
---|---|
December 31, 2023 | 0.485M |
September 30, 2023 | 0.338M |
June 30, 2023 | 0.13M |
March 31, 2023 | 0.18M |
December 31, 2022 | 0.08M |
September 30, 2022 | 0.205M |
June 30, 2022 | 0.21M |
March 31, 2022 | -4.606M |
December 31, 2021 | 8.188M |
September 30, 2021 | 11.10M |
June 30, 2021 | 28.23M |
March 31, 2021 | 43.67M |
December 31, 2020 | 56.56M |
September 30, 2020 | 52.95M |
June 30, 2020 | 47.23M |
March 31, 2020 | 37.42M |
December 31, 2019 | 16.38M |
September 30, 2019 | 17.13M |
June 30, 2019 | 8.547M |
March 31, 2019 | 10.03M |
December 31, 2018 | 9.435M |
September 30, 2018 | 9.836M |
June 30, 2018 | 7.991M |
March 31, 2018 | 7.391M |
December 31, 2017 | 4.215M |
Date | Value |
---|---|
September 30, 2017 | 3.697M |
June 30, 2017 | 7.227M |
March 31, 2017 | 5.631M |
December 31, 2016 | 4.757M |
September 30, 2016 | 4.692M |
June 30, 2016 | 0.544M |
March 31, 2016 | 4.426M |
December 31, 2015 | 9.66M |
September 30, 2015 | 12.71M |
June 30, 2015 | 13.62M |
March 31, 2015 | 11.65M |
December 31, 2014 | 12.78M |
September 30, 2014 | 2.928M |
June 30, 2014 | 1.622M |
March 31, 2014 | -0.46M |
December 31, 2013 | -6.847M |
September 30, 2013 | 14.98M |
June 30, 2013 | 25.67M |
March 31, 2013 | 27.73M |
December 31, 2012 | 28.31M |
September 30, 2012 | 13.82M |
June 30, 2012 | 4.27M |
March 31, 2012 | 2.207M |
December 31, 2011 | 1.624M |
September 30, 2011 | 1.09M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
-4.606M
Minimum
Mar 2022
56.56M
Maximum
Dec 2020
17.08M
Average
8.547M
Median
Jun 2019
Cash from Financing (TTM) Benchmarks
Perspective Therapeutics Inc | 0.785M |
Protalix BioTherapeutics Inc | 24.67M |
Electromed Inc | -0.128M |
Xtant Medical Holdings Inc | 19.69M |
Armata Pharmaceuticals Inc | 53.99M |